Navigation Links
MUHC researchers identify biomarkers that could leadto early diagnosis of colorectal cancer
Date:10/30/2013

This news release is available in French.

MONTREAL, October 30, 2013 Diagnosing colorectal cancer (CRC) is complex; it relies on significant invasive tests and subjective evaluations. This process may soon become much easier thanks to a medical breakthrough by scientists at the Research Institute of the McGill University Health Centre (RI-MUHC). The researchers have identified genetic changes in the colon lining, or mucosa, in colorectal cancer patients that could be used as biomarkers of the disease. That will allow doctors to diagnose patients earlier, more accurately and less invasively. The study, recently published online, in Cancer Prevention Research, has implications for the nearly one million people diagnosed annually worldwide.

"The gold standard of diagnosis is currently colonoscopy," says corresponding author of the study, Dr. Rima Rozen, a geneticist from the Departments of Human Genetics and Pediatrics at The Montreal Children's Hospital of the MUHC and McGill University. "This is an invasive procedure, where the physician looks for abnormal tissue or growths also known as polyps." Additionally, given surging demand for colonoscopies, this research may ultimately offer an alternative option for early diagnosis, paving the way for the reduction in wait time.

According to Dr. Rozen, who is also a researcher of the Medical Genetics and Genomics Axis at the RI-MUHC, having genetic biomarkers of CRC will enhance the diagnostic procedure. "This new method could help to avoid false negative findings, which can occur in 10 to 15 per cent of endoscopic procedures," she says. "The key is using the right genes. I believe the ones we have identified are good candidates."

Dr. Rozen and her colleagues first identified five possible abnormal marker genes in a colon cancer mouse model. They then confirmed that these candidate biomarker genes were also abnormal in tissue obtained from colon cancer patients. "Not only did this show that our mouse model mimics the human disease," says Dr. Rozen. "But more importantly, it identified genes that could be used for colorectal cancer diagnosis."

Interestingly, the abnormal patterns of these genes were detected in otherwise normal colon cells that were not near the tumor site. "CRC develops in different stages," says Dr. Rozen. "This finding suggests that it may be possible to take tissue samples in more accessible regions of the gastrointestinal tract or, ideally, in blood or stool, and look for biomarkers as an early indicator of disease."


'/>"/>

Contact: Julie Robert
julie.robert@muhc.mcgill.ca
514-934-1934 x71381
McGill University Health Centre
Source:Eurekalert

Related medicine news :

1. Unpublished trial data violates an ethical obligation to study participants, say researchers
2. Einstein researchers lead panels at NIH Aging and Chronic Disease Symposium on Geroscience
3. GW researchers examine increased ER reimbursements after ACA insurance coverage expansions
4. U of M researchers identify key proteins influencing major immune strategies
5. Researchers detail possible resistance mechanisms of colorectal cancer to bevacizumab (Avastin)
6. Carnegie Mellon and University at Buffalo researchers improving transit for people with disabilities
7. Researchers discover a new protein fold with a transport tunnel
8. Mount Sinai Researchers Identify Mechanisms and Potential Biomarkers of Tumor Cell Dormancy
9. Study by researchers at Saarland University demonstrates preventive effect of sterols in Alzheimers
10. Neurotoxin effectively relieves bone cancer pain in dogs, Penn researchers find
11. Mount Sinai Researchers Find Value -- and Limitations -- of Patient Assistance Programs for Women with Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... ... to renovate and improve the Ramsey County Medical Examiners Facility located in Saint ... the $2.5 million project is scheduled to start in late 2017/early 2018. ...
(Date:7/21/2017)... ... ... Bernard R. Bach, Jr., MD, orthopaedic surgeon at Rush University Medical Center ... Medicine (AOSSM) , received the 2017 Robert E. Leach Sports Medicine Leadership award on ... award is given annually to honor those who have made a significant contribution to ...
(Date:7/21/2017)... ... 21, 2017 , ... MedMatchPlus+ has launched a residency application ... a residency in a United States hospital. Being accepted into a residency is ... to data released by the ECFMG®, every year, 50 percent of international medical ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the first ... the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related functions ... activity levels decline over time. The study, presented today at the American ...
(Date:7/20/2017)... ... July 20, 2017 , ... ChenMed , a leading provider of value-based ... Medical Center as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor ... Medical Officer of Ambulatory Services for the UVA Health System, brings 30 years of ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... CARLSBAD, Calif. , July 10, 2017  The ... in Boston, MA at the ... unequaled value and unparalleled access to global decision makers ... to draw 800+ life science leaders during two impactful ... Boston, and provides delegates with additional networking opportunities with ...
(Date:7/6/2017)... , July 6, 2017 ThriveRx, the nutrition division of ... their families to thrive on nutrition support. To celebrate its ... new site has a fresh new look with improved organization to create ... ... ...
(Date:7/5/2017)... JERUSALEM , July 5, 2017 ... www.oramed.com ), a clinical-stage pharmaceutical company ... today that it has received approval from the Israel Securities ... Stock Exchange (TASE). Oramed common stock will commence trading on ... Based on the current market capitalization of the Company, it ...
Breaking Medicine Technology: